Forest Labs Inc (NYSE:FRX)

CAPS Rating: 3 out of 5

The Company and its subsidiaries develop, manufacture and sell both branded and generic forms of ethical drug products which require a physician's prescription, as well as non-prescription pharmaceutical products sold over-the-counter.

Results 1 - 20 of 66 : 1 2 3 4 Next »

Recs

0
Member Avatar line70day (30.08) Submitted: 2/5/2014 12:49:52 PM : Outperform Start Price: $66.60 FRX Score: +30.60

FRX Has lost 50% of its sales lost patent for Lexapro 2012 . Best seller Mamenda loses patent protection in 2015 . Sales & drugs launched over past three years Totaled $375 M. in 4th.Q. up 60% from a year ago. Have bought from Marck several drtgs should go a long way to over come loses

Recs

0
Member Avatar sharktrade (< 20) Submitted: 1/8/2014 11:31:36 AM : Outperform Start Price: $67.86 FRX Score: +32.94

a tester en bio

Recs

0
Member Avatar tmcgoldrick (< 20) Submitted: 10/28/2013 10:57:53 AM : Outperform Start Price: $46.98 FRX Score: +88.47

The new CEO has a tremendous history of success

Recs

0
Member Avatar Teacherman333 (64.51) Submitted: 5/15/2013 11:18:17 AM : Outperform Start Price: $38.15 FRX Score: +125.38

For reference point and to allow for comments by others. As of the end of March, 2013.

ROE 0.57%
Trailing PE N/A
PB 1.82
Div yield N/A

Recs

0
Member Avatar scrubs62074 (89.49) Submitted: 2/20/2013 10:59:26 AM : Outperform Start Price: $36.50 FRX Score: +128.35

Bullish MACD crossover on 02/20/13

Recs

0
Member Avatar ronmeyers50 (< 20) Submitted: 9/9/2012 12:21:49 PM : Outperform Start Price: $35.59 FRX Score: +127.51

Icahn will be working from within to unlock the value that is already there.

Recs

0
Member Avatar RugbyViking13 (92.42) Submitted: 8/15/2012 6:48:23 PM : Outperform Start Price: $33.68 FRX Score: +139.32

Drug companies always find a way

Recs

0
Member Avatar Fish08 (71.16) Submitted: 5/21/2012 2:10:17 PM : Outperform Start Price: $33.52 FRX Score: +130.75

Good firm available for less than 10x anuual R&D and a PE of 18.

Recs

0
Member Avatar stationfool (65.43) Submitted: 1/26/2012 12:03:48 PM : Outperform Start Price: $31.53 FRX Score: +148.95

no debt

Recs

0
Member Avatar shake656 (24.60) Submitted: 11/7/2011 5:38:11 PM : Outperform Start Price: $30.66 FRX Score: +151.23

Under priced.

Recs

0
Member Avatar hoboinvest (53.22) Submitted: 4/8/2011 11:25:28 PM : Outperform Start Price: $32.98 FRX Score: +136.96

One word, MRSA. They have the drug to fight it.

Recs

0
Member Avatar jemsa (< 20) Submitted: 3/28/2011 1:01:09 PM : Outperform Start Price: $31.01 FRX Score: +153.09

Value Stocks Screen Multiple Ratios

Recs

0
Member Avatar sandeeparoras (69.48) Submitted: 12/9/2010 5:34:07 AM : Outperform Start Price: $32.13 FRX Score: +133.95

Technical Indicator: LCR-20

Recs

0
Member Avatar H20jo52 (79.88) Submitted: 10/15/2010 10:03:57 AM : Outperform Start Price: $33.27 FRX Score: +115.64

patents that it holds

Recs

0
Member Avatar bobmacmaster (< 20) Submitted: 10/10/2010 11:11:33 AM : Outperform Start Price: $31.89 FRX Score: +126.80

This company has carved out a profitable niche

Recs

0
Member Avatar cashman79 (68.87) Submitted: 9/15/2010 9:55:36 AM : Outperform Start Price: $30.68 FRX Score: +131.96

watch

Recs

0
Member Avatar citizenryan (83.32) Submitted: 8/17/2010 6:34:46 PM : Outperform Start Price: $27.99 FRX Score: +156.31

This is the one of the the hardest stock to predict. Lexapro is the 2nd most prescribed drug in America. Government rules regarding patents mean the drug will go generic in 2012. This means FRX's major revenue stream will dry up.

In 2011 people will start selling. Until then it's do well.

With no end in sight for the recession people will continue to be depressed and doctors will prescribe anti-depressant. There is plenty of research on the relationship between recessions (or future outlooks) and depression

Recs

0
Member Avatar cibient (27.77) Submitted: 6/10/2010 2:49:55 PM : Outperform Start Price: $25.72 FRX Score: +183.92

MFI Top 50, amazing balance sheet, $500M stock buyback program.

Recs

0
Member Avatar DDSDH (< 20) Submitted: 6/2/2010 1:19:20 AM : Outperform Start Price: $25.55 FRX Score: +185.27

I can't find anything negative about this company. Solid all around.

Recs

0
Member Avatar CapitalBeliefs (< 20) Submitted: 5/2/2010 12:49:32 AM : Outperform Start Price: $26.98 FRX Score: +183.22

The company is shareholder focused with a strong pipeline on drugs on the horizon. The company has $2b cash to acquire licensing agreements with foreign drug companies wanting access to a non-competitor US sales team.

Trading at a 45% discount to its intrinsic value, I am looking for 20% compounded growth over the next 3 to 5 years.

Results 1 - 20 of 66 : 1 2 3 4 Next »

Featured Broker Partners


Advertisement